U.S. markets open in 4 hours 11 minutes

Vigil Neuroscience, Inc. (VIGL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.5300+0.0800 (+2.32%)
At close: 04:00PM EST
3.5800 +0.05 (+1.42%)
Pre-Market: 04:00AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close3.4500
Bid3.4500 x 800
Ask3.5200 x 4000
Day's Range3.3700 - 3.6000
52 Week Range2.8500 - 13.1000
Avg. Volume94,152
Market Cap126.647M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.0200
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.88
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for VIGL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Vigil Neuroscience, Inc.
    Analyst Report: AbbVie Inc.AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • GlobeNewswire

    Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference

    WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, and David Gray, Ph.D., Chief Science Officer, will participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on Tuesday, November 28, at 3:50 p.m.

  • GlobeNewswire

    Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE

    - Iluzanebart demonstrated favorable safety and tolerability, including no hematologic adverse events - - Clear CNS target engagement and downstream pharmacological activity at 20 mg/kg consistent with Phase 1 data; Directionally supportive changes in individual patients at 6 months on MRI and NfL biomarkers - - Natural History Study continued to provide critical insights on MRI and NfL biomarkers; sCSF1R emerging as key biomarker of ALSP disease pathology - - Company expects to report Phase 2 I

  • GlobeNewswire

    Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update

    – Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in ALSP on track for this quarter – – First participant dosed in Phase 1 study of VG-3927, the first and only small molecule TREM2 agonist in clinical development for potential treatment of Alzheimer’s disease – – Announced VGL101 complete Phase 1 data analysis and Phase 2 IGNITE trial design at 2023 ANA Annual Meeting – WATERTOWN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a cli